No difference in survival after HLA mismatched versus HLA matched allogeneic stem cell transplantation in Ewing sarcoma patients with advanced disease.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
16
03
2020
accepted:
10
12
2020
revised:
09
12
2020
pubmed:
31
1
2021
medline:
27
7
2021
entrez:
30
1
2021
Statut:
ppublish
Résumé
Patients with advanced Ewing sarcoma (AES) carry a poor prognosis. Retrospectively, we analyzed 66 AES patients treated with allogeneic stem cell transplantation (allo-SCT) receiving HLA-mismatched (group A, n = 39) versus HLA-matched grafts (group B, n = 27). Median age at diagnosis was 13 years, and 15 years (range 3-49 years) at allo-SCT. The two groups did not differ statistically in distribution of gender, age, remission status/number of relapses at allo-SCT, or risk stratum. 9/39 (23%) group A versus 2/27 (7%) group B patients developed severe acute graft versus host disease (GvHD). Of patients alive at day 100, 7/34 (21%) group A versus 9/19 (47%) group B patients had developed chronic GvHD. In group A, 33/39 (85%) versus 20/27 (74%) group B patients died of disease and 1/39 (3%) versus 1/27 (4%) patients died of complications, respectively. Altogether 12/66 (18%) patients survived in CR. Median EFS 24 months after allo-SCT was 20% in both groups, median OS was 27% (group A) versus 17% (group B), respectively. There was no difference in EFS and OS in AES patients transplanted with HLA-mismatched versus HLA-matched graft in univariate and multivariate analyses. In this analysis, CR at allo-SCT is a condition for survival (p < 0.02).
Identifiants
pubmed: 33514918
doi: 10.1038/s41409-020-01200-x
pii: 10.1038/s41409-020-01200-x
pmc: PMC8263340
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1550-1557Commentaires et corrections
Type : ErratumIn
Références
Barrett D, Fish JD, Grupp SA. Autologous and allogeneic cellular therapies for high-risk pediatric solid tumors. Pediatr Clin North Am. 2010;57:47–66. https://doi.org/10.1016/j.pcl.2010.01.001 . e-pub ahead of print 2010/03/24
doi: 10.1016/j.pcl.2010.01.001
pubmed: 20307711
pmcid: 3257217
Bouchlaka MN, Redelman D, Murphy WJ. Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects. Immunotherapy. 2010;2:399–418. https://doi.org/10.2217/imt.10.20 . e-pub ahead of print 2010/07/20
doi: 10.2217/imt.10.20
pubmed: 20635904
Doorduijn EM, Sluijter M, Salvatori DC, Silvestri S, Maas S, Arens R, et al. CD4+ T cell and NK cell interplay key to regression of MHC class Ilow tumors upon TLR7/8 agonist therapy. Cancer Immunol Res. 2017;5:642–53. https://doi.org/10.1158/2326-6066.CIR-16-0334 . e-pub ahead of print 2017/06/24
doi: 10.1158/2326-6066.CIR-16-0334
pubmed: 28637878
Schlegel P, Feuchtinger T, Nitschke-Gerard C, Seidel UJ, Lang AM, Kyzirakos C, et al. Favorable NK cell activity after haploidentical hematopoietic stem cell transplantation in stage IV relapsed Ewing’s sarcoma patients. Bone marrow Transplant. 2015;50(Suppl 2):S72–S76. https://doi.org/10.1038/bmt.2015.100 . e-pub ahead of print 2015/06/04
doi: 10.1038/bmt.2015.100
pubmed: 26039213
Perez-Martinez A, de Prada Vicente I, Fernandez L, Gonzalez-Vicent M, Valentin J, Martin R, et al. Natural killer cells can exert a graft-vs-tumor effect in haploidentical stem cell transplantation for pediatric solid tumors. Exp Hematol. 2012;40:882–91 e881. https://doi.org/10.1016/j.exphem.2012.07.004 . e-pub ahead of print 2012/07/10
doi: 10.1016/j.exphem.2012.07.004
pubmed: 22771496
Foley B, Felices M, Cichocki F, Cooley S, Verneris MR, Miller JS. The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT). Immunol Rev. 2014;258:45–63. https://doi.org/10.1111/imr.12157 . e-pub ahead of print 2014/02/13
doi: 10.1111/imr.12157
pubmed: 24517425
pmcid: 3927144
Ruggeri L, Mancusi A, Burchielli E, Capanni M, Carotti A, Aloisi T, et al. NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. Blood Cells Mol Dis. 2008;40:84–90. https://doi.org/10.1016/j.bcmd.2007.06.029 . e-pub ahead of print 2007/10/30
doi: 10.1016/j.bcmd.2007.06.029
pubmed: 17964828
Thiel U, Wawer A, Wolf P, Badoglio M, Santucci A, Klingebiel T, et al. No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. Ann Oncol. 2011;22:1614–21. https://doi.org/10.1093/annonc/mdq703 . e-pub ahead of print 2011/01/20
doi: 10.1093/annonc/mdq703
pubmed: 21245159
Grobner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA, et al. The landscape of genomic alterations across childhood cancers. Nature. 2018;555:321–7. https://doi.org/10.1038/nature25480 . e-pub ahead of print 2018/03/01
doi: 10.1038/nature25480
pubmed: 29489754
Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499:214–8. https://doi.org/10.1038/nature12213 . e-pub ahead of print 2013/06/19
doi: 10.1038/nature12213
pubmed: 23770567
pmcid: 3919509
Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang KY, Ferrone S, et al. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer. 2013;133:624–36. https://doi.org/10.1002/ijc.28070 . e-pub ahead of print 2013/02/01
doi: 10.1002/ijc.28070
pubmed: 23364915
pmcid: 3663913
Merchant MS, Bernstein D, Amoako M, Baird K, Fleisher TA, Morre M, et al. Adjuvant immunotherapy to improve outcome in high-risk pediatric sarcomas. Clin Cancer Res. 2016;22:3182–91. https://doi.org/10.1158/1078-0432.CCR-15-2550 . e-pub ahead of print 2016/01/30
doi: 10.1158/1078-0432.CCR-15-2550
pubmed: 26823601
pmcid: 7831150
Bae J, Hideshima T, Tai YT, Song Y, Richardson P, Raje N, et al. Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors. Leukemia. 2018. https://doi.org/10.1038/s41375-018-0062-8 . e-pub ahead of print 2018/03/01
doi: 10.1038/s41375-018-0062-8
pubmed: 29487385
pmcid: 6537609
Worst BC, van Tilburg CM, Balasubramanian GP, Fiesel P, Witt R, Freitag A, et al. Next-generation personalised medicine for high-risk paediatric cancer patients—the INFORM pilot study. Eur J Cancer. 2016;65:91–101. https://doi.org/10.1016/j.ejca.2016.06.009 . e-pub ahead of print 2016/08/02
doi: 10.1016/j.ejca.2016.06.009
pubmed: 27479119
Baird K, Fry TJ, Steinberg SM, Bishop MR, Fowler DH, Delbrook CP, et al. Reduced-intensity allogeneic stem cell transplantation in children and young adults with ultrahigh-risk pediatric sarcomas. Biol Blood Marrow Transplant. 2012;18:698–707. https://doi.org/10.1016/j.bbmt.2011.08.020 . e-pub ahead of print 2011/09/08
doi: 10.1016/j.bbmt.2011.08.020
pubmed: 21896345
Ladenstein R, Potschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O, et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol. 2010;28:3284–91. https://doi.org/10.1200/JCO.2009.22.9864 . e-pub ahead of print 2010/06/16
doi: 10.1200/JCO.2009.22.9864
pubmed: 20547982
Schober SJ, von Luettichau I, Wawer A, Steinhauser M, Salat C, Schwinger W, et al. Donor lymphocyte infusions in adolescents and young adults for control of advanced pediatric sarcoma. Oncotarget. 2018;9:22741–8. https://doi.org/10.18632/oncotarget.25228 . e-pub ahead of print 2018/06/02
doi: 10.18632/oncotarget.25228
pubmed: 29854312
pmcid: 5978262
Burdach S, van Kaick B, Laws HJ, Ahrens S, Haase R, Korholz D, et al. Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-cell transplant programs at Dusseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann Oncol. 2000;11:1451–62.
doi: 10.1023/A:1026539908115
pubmed: 11142486
Lang P, Teltschik HM, Feuchtinger T, Muller I, Pfeiffer M, Schumm M, et al. Transplantation of CD3/CD19 depleted allografts from haploidentical family donors in paediatric leukaemia. Br J Haematol. 2014;165:688–98. https://doi.org/10.1111/bjh.12810 . e-pub ahead of print 2014/03/05
doi: 10.1111/bjh.12810
pubmed: 24588540
Llosa NJ, Cooke KR, Chen AR, Gamper CJ, Klein OR, Zambidis ET, et al. Reduced-intensity haploidentical bone marrow transplantation with post-transplant cyclophosphamide for solid tumors in pediatric and young adult patients. Biol Blood Marrow Transplant. 2017;23:2127–36. https://doi.org/10.1016/j.bbmt.2017.08.012 . e-pub ahead of print 2017/08/16
doi: 10.1016/j.bbmt.2017.08.012
pubmed: 28807769
pmcid: 5986177
Rasper M, Jabar S, Ranft A, Jurgens H, Amler S, Dirksen U. The value of high-dose chemotherapy in patients with first relapsed Ewing sarcoma. Pediatr Blood Cancer. 2014;61:1382–6. https://doi.org/10.1002/pbc.25042 . e-pub ahead of print 2014/04/15
doi: 10.1002/pbc.25042
pubmed: 24729428